← Back to patent-cliff list
CAS 108-24-7
Acetic acid acetic anhydrideacetic anhydrideAcetic anhydride
Codes: (XXXI)1024528-1-c, (XXIV)101438-13-c, (II)101438-43-a, (III)101438-51-a, (II)101438-58-a, (XV)101438-71-b,(XV)101438-71-c, (XVI)101438-72-b, (II)101438-77-a, FLUTI-022, S-pantoprazole sodium-026, Ketoconazole-012, (XVI)443746-1-c +4 more
Application context (from source-drug indications)
Non-small cell lung cancerPralsetinibThyroid cancerPralsetinibMedullary thyroid cancerPralsetinibBreast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateAsthmaFluticasone Propionate/Formoterol Fumarate HydrateChronic obstructive pulmonary diseaseFluticasone Propionate/Formoterol Fumarate HydrateGastro-oesophageal reflux diseaseS-pantoprazole sodiumPeptic ulcerS-pantoprazole sodiumHaemorrhageS-pantoprazole sodiumTrauma and injuryS-pantoprazole sodiumComaS-pantoprazole sodiumAspiration pneumoniaS-pantoprazole sodiumFungal infectionNaftifine hydrochloride/KetoconazolePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelNasal congestionFluticasone PropionateAllergic rhinitisFluticasone Propionate鼻息肉Fluticasone PropionateRhinitisFluticasone Propionate扁平苔藓Fluticasone PropionateRashFluticasone PropionateCushing's syndromeKetoconazole头皮屑KetoconazolePityriasis versicolorKetoconazole皮肤念珠菌病KetoconazoleTineaKetoconazole脂溢性皮炎Ketoconazole下丘脑肥胖Setmelanotide Acetate巴德特-别德尔综合征Setmelanotide AcetateObesitySetmelanotide AcetatePrader-Willi综合征Setmelanotide Acetate垂体疾病Setmelanotide Acetate联合性垂体激素缺乏症Setmelanotide AcetateHypercalcaemiaCinacalcet HydrochlorideSecondary hyperparathyroidismCinacalcet HydrochlorideHyperparathyroidismCinacalcet HydrochloridePrimary hyperparathyroidismCinacalcet HydrochlorideChronic renal impairmentCinacalcet HydrochlorideCardiogenic oedemaCinacalcet HydrochloridePlaque psoriasisMufemilastUlcerative colitisMufemilastBehçet's syndromeMufemilastPsoriasisMufemilastChronic obstructive pulmonary diseaseMufemilastAtopic dermatitisMufemilastInfluenza virus infectionNorketotifenAllergic conjunctivitisNorketotifenAllergic rhinitisNorketotifen
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Pralsetinib | Tier C — Watch / trade | 2031 |
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Fluticasone Propionate/Formoterol Fumarate Hydrate | Tier C — Watch / trade | - |
| S-pantoprazole sodium | Tier C — Watch / trade | - |
| Naftifine hydrochloride/Ketoconazole | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
| Fluticasone Propionate | Tier B — Position early | - |
| Ketoconazole | Tier C — Watch / trade | - |
| Setmelanotide Acetate | Tier C — Watch / trade | - |
| Cinacalcet Hydrochloride | Tier B — Position early | - |
| Mufemilast | Tier C — Watch / trade | - |
| Norketotifen | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-[6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethan-1-one→4-Fluoro-1H-pyrazole→2,2,3,3-Tetrafluoropropan-1-ol→4-(2,2,3,3-Tetrafluoropropyl)morpholine→4-Methyl-4-(2,2,3,3-tetrafluoropropyl)morpholin-4-ium mesylate→1,2-Diazole→4-Methyl-4-[(1Z)-2,3,3-trifluoroprop-1-en-1-yl]morpholin-4-ium methanesulfonate→(2Z)-2-Fluoro-3-(morpholin-4-yl)prop-2-enal→Hydrazine dihydrochloride→4-Fluoro-1H-pyrazole hydrogen chloride→5-Bromo-2-chloropyridine→Acetic acid acetic anhydride→1-(6-Chloropyridin-3-yl)ethanone
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(3aS,9aS,10S,11aR,13aS,13bR,13cS)-13a-Hydroxy-6,9a,14,14-tetramethyl-10-[(triethylsilyl)oxy]-4,5,9a,10,11,11a,13,13a,13b,13c-decahydro-3a,7-methano[1,3]dioxolo[9,10]cyclodeca[1,2-d][1]benzoxete-2,8(9H)-dione→Acetic acid acetic anhydride→(2alpha,5beta,7beta,9beta,10beta)-4,10-Diacetoxy-1,9-dihydroxy-7-[(triethylsilyl)oxy]-5,20-epoxytax-11-en-2-yl benzoate→(3aS,9aS,10S,11aR,13aS,13bR,13cS)-6,9a,14,14-Tetramethyl-2,8-dioxo-10-[(triethylsilyl)oxy]-4,5,8,9,9a,10,11,11a,13b,13c-decahydro-3a,7-methano[1,3]dioxolo[9,10]cyclodeca[1,2-d][1]benzoxet-13a(13H)-yl acetate→Lithiumbenzene→(2alpha,5beta,7beta)-4-Acetoxy-1-hydroxy-10-oxo-7-[(triethylsilyl)oxy]-5,20-epoxytax-11-en-2-yl benzoate→(2alpha,5beta,7beta,9beta)-4-Acetoxy-1,9-dihydroxy-10-oxo-7-[(triethylsilyl)oxy]-5,20-epoxytax-11-en-2-yl benzoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-1,7,10,13-tetrahydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→Acetic acid acetic anhydride→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1,7,13-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1,13-dihydroxy-9-oxo-7-[[(2,2,2-trichloroethoxy)carbonyl]oxy]-5,20-epoxytax-11-en-2-yl benzoate→(3R,4S)-1-Benzoyl-4-phenyl-3-(triethylsiloxy)azetidin-2-one→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1-hydroxy-9-oxo-13-([(2R,3S)-3-phenyl-3-[(phenylcarbonyl)amino]-2-[(triethylsilyl)oxy]propanoyl]oxy)-7-[[(2,2,2-trichloroethoxy)carbonyl]oxy]-5,20-epoxytax-11-en-2-yl benzoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-13-[[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-1,10-dihydroxy-9-oxo-13-([(2R,3S)-3-phenyl-3-[(phenylcarbonyl)amino]-2-[(triethylsilyl)oxy]propanoyl]oxy)-7-[(triethylsilyl)oxy]-5,20-epoxytax-11-en-2-yl benzoate→Acetic acid acetic anhydride→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1-hydroxy-9-oxo-13-([(2R,3S)-3-phenyl-3-[(phenylcarbonyl)amino]-2-[(triethylsilyl)oxy]propanoyl]oxy)-7-[(triethylsilyl)oxy]-5,20-epoxytax-11-en-2-yl benzoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(Acetyloxy)-1,7,10,13-tetrahydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→Acetic acid acetic anhydride→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-1,7,13-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(2R,4S,5R)-2-(4-Methoxyphenyl)-4-phenyl-3-[(prop-2-en-1-yloxy)carbonyl]-1,3-oxazolidine-5-carboxylic acid→5-[(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-2-(benzoyloxy)-1-hydroxy-9-oxo-7-[(triethylsilyl)oxy]-5,20-epoxytax-11-en-13-yl] 3-prop-2-en-1-yl (2R,4S,5R)-2-(4-methoxyphenyl)-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate→5-[(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-2-(benzoyloxy)-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-13-yl] 3-prop-2-en-1-yl (2R,4S,5R)-2-(4-methoxyphenyl)-4-phenyl-1,3-oxazolidine-3,5-dicarboxylate→(2alpha,5beta,7beta,10beta,13alpha)-4,10-Bis(acetyloxy)-2-(benzoyloxy)-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-13-yl (2R,4S,5R)-2-(4-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.